Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Mirati Therapeutics

2023 · Acquisition/Merger · $4.8B · Complete

Announcement Sentiment

83

Strongly positive

Outcome Score

66

Largely worked — most objectives met.

BMS acquired Mirati Therapeutics for $4.8B for targeted cancer therapies.

Key facts

Announced Oct 08, 2023
Closed Jan 23, 2024
Deal value $4.8B
Deal type Acquisition/Merger
Therapeutic area Oncology

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals